<ARTICLE> 5 <LEGEND> THIS SCHEDULE CONTAINS SUMMARY FINANCIAL INFORMATION EXTRACTED FROM THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS CONTAINED IN THE COMPANY'S QUARTERLY REPORT ON FORM 10-Q FOR THE QUARTER ENDED MARCH 31, 2000 AND IS QUALIFIED IN ITS ENTIRETY BY REFERENCE TO SUCH FINANCIAL STATEMENTS. </LEGEND> <MULTIPLIER> 1,000,000 <PERIOD-TYPE> 3-MOS <FISCAL-YEAR-END> DEC-31-2000 <PERIOD-START> JAN-01-2000 <PERIOD-END> MAR-31-2000 <CASH> 126 <SECURITIES> 1,354 <RECEIVABLES> 282 <ALLOWANCES> 23 <INVENTORY> 238 <CURRENT-ASSETS> 2,154 <PP&E> 2,404 <DEPRECIATION> 808 <TOTAL-ASSETS> 4,265 <CURRENT-LIABILITIES> 731 <BONDS> 223 <PREFERRED-MANDATORY> 0 <PREFERRED> 0 <COMMON> 0 <OTHER-SE> 3,311 <TOTAL-LIABILITY-AND-EQUITY> 4,265 <SALES> 698 <TOTAL-REVENUES> 814 <CGS> 86 <TOTAL-COSTS> 86 <OTHER-EXPENSES> 190<F1> <LOSS-PROVISION> 0 <INTEREST-EXPENSE> 4 <INCOME-PRETAX> 385 <INCOME-TAX> 119 <INCOME-CONTINUING> 266 <DISCONTINUED> 0 <EXTRAORDINARY> 0 <CHANGES> 0 <NET-INCOME> 266 <EPS-BASIC> 0.26 <EPS-DILUTED> 0.25 <FN> <F1>Item consists of research and development expenses. </FN>